SURE DENMARK/SWEDEN: A Multi-centre, Prospective, Non-interventional Study Investigating the Effectiveness of Once-weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SURE DENMARK/SWEDEN
- Sponsors Novo Nordisk
- 18 Nov 2019 Planned End Date changed from 4 Feb 2020 to 19 Feb 2020.
- 08 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 03 Jul 2019 Planned End Date changed from 29 Jul 2020 to 4 Feb 2020.